[go: up one dir, main page]

MX2018014938A - Combinaciones farmaceuticas para el tratamiento del cancer. - Google Patents

Combinaciones farmaceuticas para el tratamiento del cancer.

Info

Publication number
MX2018014938A
MX2018014938A MX2018014938A MX2018014938A MX2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combinations
treating cancer
cancer
pharmaceutical
combinations
Prior art date
Application number
MX2018014938A
Other languages
English (en)
Other versions
MX379026B (es
Inventor
Bausch Alexander
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Publication of MX2018014938A publication Critical patent/MX2018014938A/es
Publication of MX379026B publication Critical patent/MX379026B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a combinaciones farmacéuticas que comprenden un agonista de PPAR y un inhibidor de P38 para usar en un método para la prevención, el retraso de la progresión o el tratamiento del cáncer.
MX2018014938A 2016-06-08 2017-06-06 Combinaciones farmaceuticas para el tratamiento del cancer MX379026B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16173443 2016-06-08
PCT/EP2017/063714 WO2017211830A1 (en) 2016-06-08 2017-06-06 Pharmaceutical combinations for treating cancer

Publications (2)

Publication Number Publication Date
MX2018014938A true MX2018014938A (es) 2019-05-16
MX379026B MX379026B (es) 2025-03-10

Family

ID=56132777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014938A MX379026B (es) 2016-06-08 2017-06-06 Combinaciones farmaceuticas para el tratamiento del cancer

Country Status (26)

Country Link
US (2) US11285155B2 (es)
EP (1) EP3468604B1 (es)
JP (2) JP7349790B2 (es)
KR (1) KR102437685B1 (es)
CN (2) CN109414506B (es)
AU (1) AU2017277478B2 (es)
BR (1) BR112018075135A2 (es)
CA (1) CA3023392C (es)
CL (1) CL2018003509A1 (es)
CO (1) CO2018013020A2 (es)
CY (1) CY1124123T1 (es)
DK (1) DK3468604T3 (es)
EA (1) EA201892287A1 (es)
ES (1) ES2866883T3 (es)
HU (1) HUE053648T2 (es)
IL (1) IL263407B (es)
MX (1) MX379026B (es)
MY (1) MY195671A (es)
PE (1) PE20190376A1 (es)
PH (1) PH12018550186A1 (es)
PL (1) PL3468604T3 (es)
PT (1) PT3468604T (es)
SG (1) SG11201809882XA (es)
UA (1) UA123914C2 (es)
WO (1) WO2017211830A1 (es)
ZA (1) ZA201900052B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
EP3468604B1 (en) * 2016-06-08 2021-01-20 Support-Venture GmbH Pharmaceutical combinations for treating cancer
WO2018033543A1 (en) * 2016-08-17 2018-02-22 Support-Venture Gmbh Method of preventing or treating hearing loss
EA201990512A1 (ru) * 2016-08-18 2019-08-30 Интекрин Терапьютикс, Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG11202012775SA (en) * 2018-07-13 2021-02-25 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE60206363T2 (de) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
US6852141B2 (en) * 2001-06-06 2005-02-08 Donaldson Company, Inc. Filter element having center piece and methods
CN1771034A (zh) * 2002-01-14 2006-05-10 法马西亚公司 过氧化物酶体增殖物激活受体－α激动剂和环加氧酶－2选择性抑制剂的组合及其治疗用途
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1885181A2 (en) * 2005-05-23 2008-02-13 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
AU2007257959A1 (en) * 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
CA2690327A1 (en) 2007-06-15 2008-12-18 Thomas P. Cleary A novel process for the preparation of 3-amino-pentan-1,5-diol
US8969350B2 (en) * 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
WO2011100769A2 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
EP3468604B1 (en) * 2016-06-08 2021-01-20 Support-Venture GmbH Pharmaceutical combinations for treating cancer

Also Published As

Publication number Publication date
CN115105601A (zh) 2022-09-27
JP7349790B2 (ja) 2023-09-25
SG11201809882XA (en) 2018-12-28
MX379026B (es) 2025-03-10
US11285155B2 (en) 2022-03-29
IL263407B (en) 2021-09-30
EP3468604B1 (en) 2021-01-20
CL2018003509A1 (es) 2019-03-15
PH12018550186A1 (en) 2019-03-18
HUE053648T2 (hu) 2021-07-28
JP2022046526A (ja) 2022-03-23
ES2866883T3 (es) 2021-10-20
AU2017277478B2 (en) 2023-03-16
CY1124123T1 (el) 2022-05-27
EP3468604A1 (en) 2019-04-17
WO2017211830A1 (en) 2017-12-14
ZA201900052B (en) 2021-10-27
DK3468604T3 (da) 2021-04-19
CN109414506A (zh) 2019-03-01
US20190160072A1 (en) 2019-05-30
BR112018075135A2 (pt) 2019-03-26
PL3468604T3 (pl) 2021-07-12
AU2017277478A1 (en) 2018-11-22
PT3468604T (pt) 2021-04-06
JP2019517562A (ja) 2019-06-24
CA3023392C (en) 2024-02-06
KR102437685B1 (ko) 2022-08-29
PE20190376A1 (es) 2019-03-08
EA201892287A1 (ru) 2019-06-28
UA123914C2 (uk) 2021-06-23
MY195671A (en) 2023-02-03
IL263407A (en) 2018-12-31
US20220175786A1 (en) 2022-06-09
CA3023392A1 (en) 2017-12-14
CO2018013020A2 (es) 2018-12-28
CN109414506B (zh) 2022-06-03
KR20190017756A (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018002359A1 (es) Métodos para usar agonistas de fxr
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
DOP2017000111A (es) Inhibidor de cinasa aurora a
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
MX393976B (es) Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2019009304A (es) Tratamiento para el cancer.
MX2017009246A (es) Farmaco de combinacion.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.